| |
LSILa
|
HSIL
|
CC
|
HSILa
|
CC
|
|---|
|
OR
|
OR
|
CI
|
p
|
OR
|
CI
|
p
|
OR
|
OR
|
CI
|
p
|
|---|
|
TOP2A/MCM2
|
1.0
|
44.9
|
16.6–121.4
|
< 0.001
|
167.4
|
43.1–∞
|
< 0.001
|
1.0
|
2.6
|
0.6–∞
|
0.183
|
|
p16INK4a
|
1.0
|
16.2
|
6.7–38.9
|
< 0.001
|
51.3
|
14.4–∞
|
< 0.001
|
1.0
|
1.9
|
0.5–∞
|
0.312
|
|
Cyclin E
|
1.0
|
13.1
|
5.8–29.9
|
< 0.001
|
78.5
|
21.7–∞
|
< 0.001
|
1.0
|
3.9
|
0.9–∞
|
0.060
|
|
Ki-67
|
1.0
|
17.7
|
7.5–41.4
|
< 0.001
|
89.0
|
24.1–∞
|
< 0.001
|
1.0
|
2.4
|
0.7–∞
|
0.146
|
|
Telomerase
|
1.0
|
6.1
|
2.5–14.6
|
< 0.001
|
15.6
|
4.5–∞
|
< 0.001
|
1.0
|
1.4
|
0.4–∞
|
0.562
|
|
RI-5
|
1.0
|
72.7
|
21.8–242.2
|
< 0.001
|
261
|
56.5–∞
|
< 0.001
|
1.0
|
2.8
|
0.7–∞
|
0.152
|
|
RI-4
|
1.0
|
55.2
|
18.1–168.3
|
< 0.001
|
203.3
|
47.3–∞
|
< 0.001
|
1.0
|
3.0
|
0.8–∞
|
0.110
|
|
RI-3
|
1.0
|
79.1
|
23.7–264.4
|
< 0.001
|
246.1
|
55.8–∞
|
< 0.001
|
1.0
|
2.8
|
0.7–∞
|
0.140
|
|
RI-2
|
1.0
|
61.4
|
20.0–188.8
|
< 0.001
|
200.8
|
44.1–∞
|
< 0.001
|
1.0
|
2.2
|
0.6–∞
|
0.224
|
|
ROS
|
1.0
|
0.7
|
0.5–1.0
|
0.055
|
0.3
|
0.2–0.5
|
0.30
|
1.0
|
0.4
|
0.2–0.7
|
0.003
|
|
8-OHdG
|
1.0
|
0.8
|
0.5–1.2
|
0.321
|
1.2
|
0.7–1.9
|
0.487
|
1.0
|
1.2
|
0.7–2.1
|
0.415
|
- LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E, and RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) areference category
